Investments

As part of ABC2’s mission bringing together the best and the brightest to advance brain cancer therapies, ABC2 invests in early stage biotech companies and collaborates with multi-national pharmaceutical companies. Our venture philanthropy approach drives the development of drugs that might otherwise not move forward. We don't view ourselves as simply investors, we are value-added partners who not only provide capital but deep domain expertise and contacts. We actively engage with our portfolio companies to help shape the direction of the research and move treatments as fast as possible from basic discovery to the clinic. Here are some of our most recent investments:

Title: Rapidly Repurposing FDA-Approved Drugs to Treat Brain Cancer
Investigator: Matt De Silva
Grantee: Notable Labs

Title: MicroRNA as a Biomarker Platform for Glioblastoma Testing
Investigators: Clark Chen, Bob Carter
Grantees: University of California San Diego, Regulus Therapeutics

Title: Expenditure Responsibility Grant to Test Brain Cancer Therapies Being Developed
Grantee: Agios Pharmaceuticals

Title: Expenditure Responsibility Grant to Test Brain Cancer Therapies Being Developed
Grantee: Tocagen

Title:  FDA Approval for Avastin - a new glioblastoma treatment
Grantee: Genentech